tradmap

MLTX Earnings Moonlake Immunotherapeutics

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$7 -$3 $0 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$227M -$114M $0 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-102% -32% 39% 0% 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$3 -$1 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$70M -$35M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-27% -14% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–21 of 21
Q2 20262026-06-30-1.812026-08-1010-Q
Q1 20262026-03-31-0.982026-05-1110-Q
FY 20252025-12-31-3.532026-02-2510-K
Q3 20252025-09-30-2.612025-11-0510-Q
Q2 20262025-06-30-1.502026-08-1010-Q
Q1 20262025-03-31-0.632026-05-1110-Q
FY 20252024-12-31-1.892026-02-2510-K
Q3 20252024-09-30-1.172025-11-0510-Q
Q2 20252024-06-30-0.602025-08-0510-Q
Q1 20252024-03-31-0.222025-05-1210-Q
FY 20252023-12-31-0.732026-02-2510-K
Q3 20242023-09-30-0.632024-11-0710-Q
Q2 20242023-06-30-0.462024-08-0710-Q
Q1 20242023-03-31-0.232024-05-0710-Q
FY 20242022-12-31-1.702025-02-2610-K
Q3 20232022-09-30-1.272023-11-1410-Q
Q2 20232022-06-30-1.132023-08-1010-Q
Q1 20232022-03-31-3.172023-05-1110-Q
FY 20222021-12-31-6.842023-03-2010-K
Q3 20222021-09-30-4.062022-11-1410-Q
Q2 20222021-06-30-2.112022-08-1210-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.